Lexicon Pharmaceuticals (LXRX) Other financing activities (2012 - 2026)

Lexicon Pharmaceuticals (LXRX) has 10 years of Other financing activities data on file, last reported at $65000.0 in Q1 2026.

• On a quarterly basis, Other financing activities changed N/A year-over-year to $65000.0 in Q1 2026; TTM through Mar 2026 was $65000.0, a 104.66% increase from a year earlier, with the FY2024 full-year figure at -$1.3 million, changed N/A from the prior year.
• Other financing activities for Q1 2026 stood at $65000.0, up from -$1000.0 in the prior quarter.
• Over the last five years, Other financing activities for LXRX reached as high as $94.3 million in Q3 2022 and fell as low as -$906000.0 in Q3 2024.
• Historically, Other financing activities has averaged $9.3 million across 4 years, with a median of $32000.0 in 2024.
• Across the five-year window, Other financing activities surged 392.96% in 2022 and plunged 258.96% in 2024, its largest moves.
• Year by year, Other financing activities stood at -$698000.0 in 2022, then surged by 56.02% to -$307000.0 in 2023, then soared by 99.67% to -$1000.0 in 2024, then soared by 6600.0% to $65000.0 in 2026.
• Per Business Quant data, the three most recent Other financing activities figures were $65000.0 in Q1 2026, -$1000.0 in Q4 2024, and -$906000.0 in Q3 2024.